HNC-1664 is an adenosine analog with broad-spectrum antiviral activity against positive-strand coronaviruses and negative-strand arenaviruses, inhibits SARS-CoV-2 WT strain with IC50 of 29 nM, inhibits viral RdRP activity by competing with ATP in a non-catalytic manner.
HNC-1664 robustly inhibitsSARS-CoV-2 replication in Caco-2 cells, with an IC50 value of 76 nM, and 90.28% reduction in the viral protein concentration at 10 μM, without significant cytotoxicity.
HNC-1664 robustly inhibits viral production, with IC50 values of 0.37 μM, 1.14 μM, and 0.12 μM, respectively, against ongoing SARS-CoV-2 variants of concern (VOCs) XBB.1.18.1, HK.3.1 and BF.7.14 variants in Vero E6 cell lines.
HNC-1664 exhibits high potency against these variants, with IC50 values of 0.019 μM, 0.064 μM, 0.084 μM and 0.096 μM, respectively, against prevalent emerging VOCs, including alpha, beta, delta and Omicron BA.1.
HNC-1664 reduces HCoV-229E and HCoV-OC43 replication in a dose-dependent manner.
HNC-1664 has potent broad-spectrum antiviral effects on different families of RNA viruses, including coronaviruses and arenaviruses.
HNC-1664 potently protected K18-hACE2 mice against lethal SARS-CoV-2 delta variant infection via in vivo antiviral efficacy and suppressed viral production and virus-induced pathological injury in tissues.
HNC-1664 inhibits SARS-CoV-2 and LASV RdRP activity by competing with ATP in a non-catalytic manner.